LOS ANGELES, Nov. 08, 2022 (GLOBE NEWSWIRE) — The Global Acute Repetitive Seizures Market The size accounted for USD 569 million in 2021 and is expected to reach a market size of USD 16,753 million by 2030, growing at a CAGR of 45.9% from 2022 to 2030.
Acute Repetitive Seizures Market Statistics
- Global acute repetitive seizures market revenue was USD 569 million in 2021, growing at a CAGR of 45.9% from 2022 to 2030
- North America region accounted for 36% of acute repetitive seizures market share in 2021
- The Asia-Pacific regional market is expected to grow at a CAGR of 46% from 2022 to 2030
- On the basis of product, the diastat rectal gel segment captures more than 33.9% of the overall market share in 2021
- The availability of a sophisticated product pipeline determines the market value of acute repetitive seizures
Free Sample Report Request @ https://www.acumenresearchandconsulting.com/request-sample/968
Acute Repetitive Seizures Market Report Coverage:
| Market | Acute Repetitive Seizures Market | |
| Acute Repetitive Seizures Market Size 2021 | $569 million | |
| Acute Repetitive Seizures Market Forecast 2030 | $16,753 million | |
| Acute Repetitive Seizures Market CAGR During 2022 – 2030 | 45.9% | |
| Acute Repetitive Seizures Market Analysis period | 2018 – 2030 | |
| Acute Repetitive Seizures Market base year | 2021 | |
| Acute Repetitive Seizures Market Forecast data | 2022 – 2030 | |
| Segments Covered | By product and by geography | |
| Acute Repetitive Seizures Market Regional scope | North America, Europe, Asia-Pacific, Latin America, Middle East and Africa | |
| Profiled Key Companies | Grupo Ferrer Internacional SA (ALEXZA), Valeant Pharmaceuticals North America LLC, Neurelis, Inc. and UCB SA | |
| Report cover | Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulatory Analysis | |
Acute Repetitive Seizures Market Overview
The major driver of the acute repetitive seizures market is the increase in the epilepsy awareness business. High unmet clinical demand for patients and caregivers, along with the availability of a progressive product pipeline, are some of the major drivers expected to drive the development of the market. For many patients with cluster seizures, drug therapy is effective. However, there are other treatment issues and unmet medical needs, such as drug-induced seizures, adverse effects, and lack of anti-epileptogenic drugs that may prevent seizure progression and comorbidities. associated.
Acute Repetitive Seizures Market Trends
The growth of the acute repetitive seizures market is driven by generic drugs, the majority of which are oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only drug approved in the United States, but buccal midazolam is approved in the European Union. Other drugs include midazolam (intramuscular, buccal, intranasal), diazepam (intramuscular and oral), progesterone, and lorazepam (intranasal, oral, sublingual). The industry is expected to merge with some significant companies and a large market share in terms of revenue.
There are several methods of drug delivery, with the nasal route being the most popular over others such as rectal, buccal, and parenteral. Since the pill can be administered outside of the hospital, caregivers and parents prefer the oral route for children who suffer from pediatric seizures.
Additionally, in order to reduce healthcare expenditures, governments are developing a continuous workforce to reduce hospital stays and on-site treatment costs through casualty care models such as clinics and Home Care. Developing countries such as China and India are gradually implementing such healthcare legislation, which is expected to propel the expansion of the acute repetitive seizure market.
View the report’s detailed table of contents @
https://www.acumenresearchandconsulting.com/table-of-content/acute-repetitive-seizures-market
Acute Repetitive Seizures Market Segmentation
The global acute repetitive seizures market has been segmented by Acumen Research and Consulting on the basis of product. By product, the segment is separated into NRL-1, USL-261, AZ-002, diastat rectal gel and others. Diastat Rectal Gel was the leading product sub-segment in 2021 owing to the efficient delivery method and price of the product. According to the Acute Repetitive Seizures Market forecast, the USL-21 segment is expected to grow significantly over the next few years. Due to its improved clinical characteristics and encouraging Phase III results, USL-21 has a competitive advantage over competing drugs.
Regional Overview of Acute Repetitive Seizures Market
The global acute repetitive seizures market is divided into several geographical areas: Asia-Pacific, Europe, North America, Latin America, Middle East and Africa. According to an industry analysis of acute repetitive seizures, North America captures the largest proportion in 2021. This expansion is due to factors such as increased epilepsy and seizure awareness initiatives. Germany is expected to experience lucrative growth over the next decade thanks to technological advancements in clinical, scientific and medical fields. Due to the presence of a large number of industry competitors and the high occurrence of infectious and chronic disorders, the North America acute repetitive seizures market is expected to dominate the global market during the forecast period.
In addition, the Asia Pacific Acute Repeated Crises market share is expected to grow at a significant CAGR throughout the forecast period. Dense populations, along with increasing occurrences of chronic diseases such as diabetes and cancer, are significant drivers for the expansion of the regional market.
Buy this premium research report –
https://www.acumenresearchandconsulting.com/buy-now/0/968
Acute Repetitive Seizures Market Players
Some of the leading companies in the Acute Repetitive Seizures market are Valeant Pharmaceuticals North America LLC, Grupo Ferrer Internacional SA (ALEXZA), Neurelis, Inc., and UCB SA.
Acute Repetitive Crises Market Strategies
Global players are constantly spending on R&D and developing new product portfolios to attract more business prospects from emerging markets such as India and China. Furthermore, increasing R&D investments coupled with technical improvements are expected to provide profitable prospects for industry players. UCB SA and Neurelis, Inc. Due to the commercialization of VALTOCO and USL-261, are likely to capture the majority of the global recurrent acute attack market. Since both drugs (USL-261 and VALTOCO) have been designated as orphan pharmaceuticals, their values and prices are generally high. Also, the preferable route of administration, according to research, is nasal, which will result in earlier acceptance of both of these medications.
Questions this report answers
- What was the market size of Acute Repetitive Seizures Market in 2021?
- What will be the CAGR of the Acute Repetitive Seizures Market during the forecast period from 2022 to 2030?
- Who are the key players in the Global Acute Repetitive Seizures Market?
- Which region held the largest Acute Repetitive Seizures market share in 2021?
- What are the key market drivers of Acute Repetitive Seizures Market?
- Who is the largest end-user of Acute Repetitive Crises Market?
- What will be the value of the acute repetitive seizures market in 2030?
Browse more research topics on Health sector Related:
The Global home fitness market Size taken into account $11.3 billion in 2021 and is expected to reach a market size of $17.3 billion by 2030 rising to one CAGR of 4.9% from 2022 to 2030.
The Global Fertility Testing Market Size taken into account $491.3 million in 2021 and is expected to reach a market size of $920.4 million by 2030 rising to one 7.5% CAGR from 2022 to 2030.
The Global Digital Polymerase Chain Reaction Market Size taken into account $271.6 million in 2021 and is expected to reach a market size of $1,379.6 million by 2030 rising to one CAGR of 19.9% from 2022 to 2030.
About Acumen Research and Consulting:
Acumen Research and Consulting is a global provider of information and consulting services in the information technology, investment, telecommunications, manufacturing and consumer technology markets. ARC helps investment communities, IT professionals, and business leaders make fact-based decisions about technology purchases and develop business growth strategies to compete in the marketplace . With a team of over 100 analysts and a collective industry experience of over 200 years, Acumen Research and Consulting ensures to provide a combination of industry knowledge with global and national level expertise.
For the latest update, follow us on Twitter and, LinkedIn
Contact us:
Mr. Richard Johnson
Acumen Research and Consulting
USA: +13474743864
India: +918983225533
E-mail: sales@acumenresearchandconsulting.com
#Acute #repetitive #seizures #market #size #expected #reach #USD #million #registering #CAGR #driven #unmet #clinical #patients #caregivers